The trastuzumab market is anticipated to grow at a significant CAGR of 14.4% during the forecast period (2022-2028). Trastuzumab is a monoclonal immune response that is superior to other options for treating breast cancer. It is especially useful for bosom cancers that express the human epidermal growth factor receptor 2 (HER2) protein. It is usually […]
